Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Alzheimers Dis ; 2014: 431858, 2014.
Article in English | MEDLINE | ID: mdl-25097793

ABSTRACT

Alzheimer's disease is the most prevalent cause of dementia and is associated with accumulation of amyloid-ß peptide (Aß), particularly the 42-amino acid Aß1-42, in the brain. Aß1-42 levels can be decreased by γ-secretase modulators (GSM), which are small molecules that modulate γ-secretase, an enzyme essential for Aß production. BMS-869780 is a potent GSM that decreased Aß1-42 and Aß1-40 and increased Aß1-37 and Aß1-38, without inhibiting overall levels of Aß peptides or other APP processing intermediates. BMS-869780 also did not inhibit Notch processing by γ-secretase and lowered brain Aß1-42 without evidence of Notch-related side effects in rats. Human pharmacokinetic (PK) parameters were predicted through allometric scaling of PK in rat, dog, and monkey and were combined with the rat pharmacodynamic (PD) parameters to predict the relationship between BMS-869780 dose, exposure and Aß1-42 levels in human. Off-target and safety margins were then based on comparisons to the predicted exposure required for robust Aß1-42 lowering. Because of insufficient safety predictions and the relatively high predicted human daily dose of 700 mg, further evaluation of BMS-869780 as a potential clinical candidate was discontinued. Nevertheless, BMS-869780 demonstrates the potential of the GSM approach for robust lowering of brain Aß1-42 without Notch-related side effects.

2.
J Neurochem ; 129(2): 275-83, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24266811

ABSTRACT

NMDA receptor hypofunction is hypothesized to contribute to cognitive deficits associated with schizophrenia. Since direct activation of NMDA receptors is associated with serious adverse effects, modulation of the NMDA co-agonists, glycine or D-serine, represents a viable alternative therapeutic approach. Indeed, clinical trials with glycine and D-serine have shown positive results, although concerns over toxicity related to the high-doses required for efficacy remain. Synaptic concentrations of D-serine and glycine are regulated by the amino acid transporter alanine serine cysteine transporter-1 (asc-1). Inhibition of asc-1 would increase synaptic D-serine and possibly glycine, eliminating the need for high-dose systemic D-serine or glycine treatment. In this manuscript, we characterize Compound 1 (BMS-466442), the first known small molecule inhibitor of asc-1. Compound 1 selectively inhibited asc-1 mediated D-serine uptake with nanomolar potency in multiple cellular systems. Moreover, Compound 1 inhibited asc-1 but was not a competitive substrate for this transporter. Compound 1 is the first reported selective inhibitor of the asc-1 transporter and may provide a new path for the development of asc-1 inhibitors for the treatment of schizophrenia.


Subject(s)
Amino Acid Transport System y+/antagonists & inhibitors , Excitatory Amino Acid Agonists/pharmacology , Histidine/analogs & derivatives , Indoles/chemical synthesis , Indoles/pharmacology , Receptors, N-Methyl-D-Aspartate/agonists , Amino Acids/metabolism , Animals , Cell Line , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Glycine/metabolism , Histidine/chemical synthesis , Histidine/pharmacology , Humans , Rats , Rats, Sprague-Dawley , Serine/metabolism , Small Molecule Libraries , Synaptosomes/metabolism
3.
J Biomol Screen ; 12(8): 1029-41, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17989426

ABSTRACT

Ligand-induced cytoplasm to nucleus translocation is a critical event in the nuclear receptor (NR) signal transduction cascade. The development of green fluorescent proteins and their color variants fused with NRs, along with the recent developments in automated cellular imaging technologies, has provided unique tools to monitor and quantify the NR translocation events. These technology developments have important implications in the mechanistic evaluation of NR signaling and provide a powerful tool for drug discovery. The unique challenges for developing a robust NR translocation assay include cytotoxicity accompanied with chronic overexpression of NRs, basal translocation induced by serum present in culture medium, and interference from endogenous NRs, as well as subcellular dynamics. The authors have developed a robust assay system for the glucocorticoid receptor (GR) that was applied to a panel of nuclear receptor ligands. Using a high-content imaging system, ligand-induced, dose-dependent GR nuclear translocation was quantified and a correlation with other conventional assays established.


Subject(s)
Biological Assay/methods , Receptors, Glucocorticoid/metabolism , Animals , Bacterial Proteins/metabolism , Benzoquinones/pharmacology , COS Cells , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Survival/drug effects , Chlorocebus aethiops , Dexamethasone/pharmacology , HeLa Cells , Humans , Imaging, Three-Dimensional , Lactams, Macrocyclic/pharmacology , Luminescent Proteins/metabolism , Protein Transport/drug effects , Receptor Cross-Talk/drug effects , Recombinant Fusion Proteins/metabolism , Reproducibility of Results , Transcriptional Activation/drug effects
4.
Steroids ; 69(3): 201-17, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15072922

ABSTRACT

The identification of a new series of selective nonsteroidal progesterone receptor (PR) agonists is reported. Using a high-throughput screening assay based on the measurement of transactivation of a mouse mammary tumor virus promoter-driven luciferase reporter (MMTV-Luc) in human breast cancer T47D cells, a benzimidazole-2-thione analog was identified. Compound 1 showed an apparent EC50 of 53 nM and efficacy of 93% with respect to progesterone. It binds to PR with high affinity (Ki nM), but had no or very low affinity for other steroid hormone receptors. Structure-activity relationship studies of a series of benzimidazole-2-thione analogs revealed critical positions for high PR binding affinity and transactivation potency as well as receptor selectivity, as exemplified by 25. Compound 25 binds to human PR with high affinity (Ki nM) and had at least > 1000-fold selectivity for PR versus other steroid receptors. Molecular modeling studies suggested that these agonists overlap favorably with progesterone in the ligand-binding domain of PR. In T47D cells, compound 25 acted as a full agonist in the MMTV-Luc reporter assay, as well as in the induction of endogenous alkaline phosphatase activity with apparent EC50 values of 4 and 9 nM, respectively. In the immature rat model, compound 25 provided a significant suppression of estrogen-induced endometrium hypertrophy as measured by luminal epithelial height. In contrast, compound 25 was inactive in the luteinizing hormone release assay in young ovariectomized rats. These benzimidazole-2-thione analogs constitute a new series of nonsteroidal PR agonists with an excellent steroid receptor selectivity profile. The differential activities observed in the in vivo progestogenic assays in rat models suggest that these analogs can act as selective PR modulators.


Subject(s)
Benzimidazoles/pharmacology , Imidazoles/pharmacology , Receptors, Progesterone/agonists , Structure-Activity Relationship , Sulfhydryl Compounds/pharmacology , Animals , Benzimidazoles/chemical synthesis , Benzimidazoles/chemistry , Benzimidazoles/metabolism , Binding, Competitive/drug effects , Cell Line, Tumor , Female , Genes, Reporter , Humans , Imidazoles/chemical synthesis , Imidazoles/chemistry , Imidazoles/metabolism , Luteinizing Hormone/metabolism , Medroxyprogesterone Acetate/metabolism , Medroxyprogesterone Acetate/pharmacology , Models, Molecular , Molecular Conformation , Progesterone/metabolism , Progesterone/pharmacology , Protein Binding , Rats , Rats, Sprague-Dawley , Receptors, Progesterone/metabolism , Sulfhydryl Compounds/chemical synthesis , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/metabolism , Transcriptional Activation/drug effects , Uterus/drug effects , Uterus/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...